Preclinical Toxicology and Anticholangiocarcinoma Activity of Oral Formulation of Standardized Extract of Zingiber Officinale

Abstract

Cholangiocarcinoma (CCA) remains a significant public health problem in Thailand. New effective and safe drugs are urgently needed. Zingiber officinale Roscoe (ZO) is a widely used medicinal plant for the treatment of several ailments, and the animal study suggests a potential anti-CCA activity. The present study aimed to develop the oral formulation of standardized extract of ZO and investigate toxicological profiles (acute, repeated dose, and chronic toxicity), including anti-CCA activity of the ZO formulation. The oral pharmaceutical formulation of the standardized ZO extract was successfully developed with an acceptable level of contamination and physicochemical and pharmaceutical properties. Acute, subacute, and chronic toxicity tests were conducted in healthy Sprague Dawley rats according to the OECD guidelines. The results showed no evidence of toxicity and death in the acute and subacute toxicity testing with the maximum tolerated dose (MTD) of 5000 and 2000 mg/kg body weight, respectively. Chronic toxicity revealed MTD and No-Observed-Adverse-Effect level (NOAEL) of 1000 mg/kg body weight. The anti-CCA activity was evaluated in CCA-xenografted mouse model. The formulated ZO powder was fed to animals daily for 30 days. Significant anti-CCA activity on tumor growth inhibition and prolongation of survival time were demonstrated at the high (2000 mg/kg body weight) and moderate (1000 mg/kg body weight) dose levels. Further investigation to elucidate molecular targets of action of ZO against CCA cells is encouraged.

Key words

Zingiber officinale - Zingiberaceae - cholangiocarcinoma - toxicity - xenografted model

• References

• 1 Razumilava N, Gores G. Cholangiocarcinoma. The Lancet 2014; 383: 2168-2179
• 2 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016; 13: 261-280
• 3 Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Gastrointest Surg 2007; 31: 1258-1265
• 4 Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H. British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012; 61: 1657-1669
• 5 Ramirez-Merino N, Aix SP, Cortes-Funes H. Chemotherapy for cholangiocarcinoma: an update. World J Gastrointest Oncol 2013; 5: 171-176
• 6 Iwahashi S, Ishibashi H, Utsunomiya T, Morine Y, Ochir TL, Hanaoka J, Mori H, Ikemoto T, Imura S, Shimada M. Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. J Med Invest 2011; 58: 106-109
• 7 Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, Boudjema K, Fartoux L, Bouhier-Leporrier K, Jouve JL, Faroux R, Guerin-Meyer V, Kurtz JE, Assénat E, Seitz JF, Baumgaertner I, Tougeron D, de la Fouchardière C, Lombard-Bohas C, Boucher E, Stanbury T, Louvet C, Malka D, Phelip JM. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 2019; 37: 658-667
• 8 Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, Kaneoka Y, Yamamoto M, Ambo Y, Shimizu Y, Ozawa F, Fukutomi A, Ando M, Nimura Y, Nagino M. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 2018; 105: 192-202
• 9 Duke JA, Bogenschutz-Godwin MJ, duCellier J, Duke PK. Handbook of Medicinal Herbs 2nd edition. Washington, D.C.: CRC Press LLC; 2002: 308-317
• 10 Mascolo N, Jain R, Jain SC, Capasso F. Ethnopharmacologic investigation of ginger (Zingiber officinale). J Ethnopharmacol 1989; 27: 129-140
• 11 Podlogar JA, Verspohl EJ. Antiinflammatory effects of ginger and some of its components in human bronchial epithelial (BEAS-2B) cells. Phytother Res 2012; 26: 333-336
• 12 Danwilai K, Konmun J, Sripanidkulchai B, Subongkot S. Antioxidant activity of ginger extract as a daily supplement in cancer patients receiving adjuvant chemotherapy: a pilot study. Cancer Manag Res 2017; 9: 11-18
• 13 Chen HC, Chang MD, Chang TJ. Antibacterial properties of some spice plants before and after heat treatment. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1985; 18: 190-195
• 14 Martins LB, Rodrigues AMDS, Monteze NM, Tibaes JRB, Amaral MHA, Gomez RS, Teixeira AL, Ferreira AVM. Double-blind placebo-controlled randomized clinical trial of ginger (Zingiber officinale Rosc.) in the prophylactic treatment of migraine. Cephalalgia 2019; 39: 68-76
• 15 Ebrahimzadeh Attari V, Somi MH, Asghari Jafarabadi M, Ostadrahimi A, Moaddab SY, Lotfi N. The gastro-protective effect of ginger (Zingiber officinale Roscoe) in helicobacter pylori positive functional dyspepsia. Adv Pharm Bull 2019; 9: 321-324
• 16 Aryaeian N, Shahram F, Mahmoudi M, Tavakoli H, Yousefi B, Arablou T, Jafari Karegar S. The effect of ginger supplementation on some immunity and inflammation intermediate genes expression in patients with active rheumatoid arthritis. Gene 2019; 698: 179-185
• 17 Mahavorasirikul W, Viyanant V, Chaijaroenkul W, Itharat A, Na-Bangchang K. Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro . BMC Complement Altern Med 2010; 10: 55
• 18 Konmun J, Danwilai K, Ngamphaiboon N, Sripanidkulchai B, Sookprasert A, Subongkot S. A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy. Med Oncol 2017; 34: 69
• 19 Plengsuriyakarn T, Viyanant V, Eursitthichai V, Picha P, Kupradinant P, Itharat A, Na-Bangchang K. Anticancer activities against cholangiocarcinoma, toxicity and pharmacological activities of Thai medicinal plants in animal models. BMC Complement Altern Med 2012; 12: 23
• 20 Plengsuriyakarn T, Viyanant T, Eursiddhichai V, Tesana S, Chaijaroenkul W, Itharat A, Na-Bangchang K. Cytotoxicity, toxicity, and anticancer activity of Zingiber officinale Roscoe against cholangiocarcinoma. Asian Pac J Cancer Prev 2012; 13: 4597-4606
• 21 Bordia A, Verma SK, Srivastava KC. Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Trigonella foenum graecum L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 1997; 56: 379-384
• 22 Langner E, Greifenberg S, Gruenwald J. Ginger: history and use. Adv Ther 1998; 15: 25-44
• 23 Liang MH. From America: cookbook medicine or food for thought: practice guidelines development in USA. Ann Rheum Dis 1992; 51: 1257-1258
• 24 ElRokh el-SM Yassin NA, El-Shenawy SM, Ibrahim BM. Antihypercholesterolaemic effect of ginger rhizome (Zingiber officinale) in rats. Inflammopharmacology 2010; 18: 309-315
• 25 Ferri-Lagneau KF, Moshal KS, Grimes M, Zahora B, Lv L, Sang S, Leung T. Ginger stimulates hematopoiesis via Bmp pathway in zebrafish. PLoS One 2012; 7: e39327
• 26 Khosravani M, Azarbayjani MA, Abolmaesoomi M, Yusof A, Zainal AN, Rahimi E, Feizolahi F, Akbari M, Seyedjalali S, Dehghan F. Ginger extract and aerobic training reduces lipid profile in high-fat fed diet rats. Eur Rev Med Pharmacol Sci 2016; 20: 1617-1622
• 27 Zhao XX, Lu M, Zhu X, Gao P, Li YL, Wang XM, Ma DY, Guo XH, Tong BY, Yang XL, Du WW, Zhou SF, Liu HM, Ran PF, Lü XR. Multi-central clinical evaluation of ginger-partitioned moxibustion for treatment of leukopenia induced by chemotherapy. Zhongguo Zhen Jiu 2007; 27: 715-720
• 28 Shahdadi H, Nasiri AA, Sepehri Z, Poodineh Moghadam M, Kiani Z. The effect of ginger powder on blood lipid profile, fasting blood glucose, and blood pressure in hyperlipidemic men: a clinical trial study. ZBMUJ 2014; 6: 78-87
• 29 Attari VE, Mahluji S, Jafarabadi MA, Ostadrahimi A. Effects of supplementation with ginger (Zingiber officinale Roscoe) on serum glucose, lipid profile and oxidative stress in obese women: a randomized, placebo-controlled clinical trial. Pharm Sci 2015; 21: 184-191
• 30 Rong X, Peng G, Suzuki T, Yang Q, Yamahara J, Li Y. A 35-day gavage safety assessment of ginger in rats. Regul Toxicol Pharmacol 2009; 54: 118-123
• 31 Mega TP, Kocyigit SS, Kilinc O, Orun O. Biological effects of whole Z. officinale extract on chronic myeloid leukemia cell line K562. Gene 2019; 692: 217-222
• 32 Akimoto M, Iizuka M, Kanematsu R, Yoshida M, Takenaga K. Anticancer effect of ginger extract against pancreatic cancer cells mainly through reactive oxygen species-mediated autotic cell death. PLoS One 2015; 10: e0126605
• 33 Pashaei-Asl R, Pashaei-Asl F, Mostafa Gharabaghi P, Khodadadi K, Ebrahimi M, Ebrahimie E, Pashaiasl M. The inhibitory effect of ginger extract on ovarian cancer cell line; application of systems biology. Adv Pharm Bull 2017; 7: 241-249
• 34 Tuntiwechapikul W, Taka T, Songsomboon C, Kaewtunjai N, Imsumran A, Makonkawkeyoon L, Pompimon W, Lee TR. Ginger extract inhibits human telomerase reverse transcriptase and c-Myc expression in A549 lung cancer cells. J Med Food 2010; 13: 1347-1354
• 35 Plengsuriyakarn T, Viyanant V, Eursitthichai V, Itharat A, Na-Bangchang K. In vitro investigations on the potential roles of Thai medicinal plants in treatment of cholangiocarcinoma. Int J Pharm Pharmacol 2012; 2: 1-12
• 36 Dongare S, Gupta SK, Mathur R, Saxena R, Mathur S, Agarwal R. Zingiber officinale attenuates retinal microvascular changes in diabetic rats via anti-inflammatory and antiangiogenic mechanisms. Mol Vis 2016; 22: 599-609
• 37 Zhong W, Yang W, Qin Y, Gu W, Xue Y, Tang Y, Xu H, Wang H, Zhang C, Wang C, Sun B, Liu Y, Liu H, Zhou H, Chen S, Sun T, Yang C. 6-Gingerol stabilized the p-VEGFR2/VE-cadherin/β-catenin/actin complex promotes microvessel normalization and suppresses tumor progression. J Exp Clin Cancer Res 2019; 38: 285
• 38 Lee HS, Seo EY, Kang NE, Kim WK. [6]-Gingerol inhibits metastasis of MDA-MB-231 human breast cancer cells. J Nutr Biochem 2008; 19: 313-319
• 39 Thai Herbal Pharmacopoeia 2017. Available at: https://bdn.go.th/attachment/services/download.php?WP=q3MZp21CM5O0hJatrTgjWz03qmAZZz1CM5O0hJatrTDo7o3Q Accessed December 6, 2018
• 40 The United States Pharmacopoeia 41 – National Formulary 36:. United States Pharmacopeial Convention. Available at: http://www.usp.org/ Accessed May 1, 2018
• 41 European Medicines Agency. Guideline on quality of herbal medicinal products/traditional herbal medicinal products UK, European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-herbal-medicinal-products-traditional-herbal-medicinal-products_en.pdf Accessed March 31, 2011
• 42 British Pharmacopoeia UK, 2018. Available at: https://www.pharmacopoeia.com/downloads/bp/2018/ Accessed January 1, 2018
• 43 Hunt DG, Chandler C, Ulrich DA, Poska R, Montero A. USP controlled room temperature range expansion. Pharmacopeial Forum 2013; 39: 1-5
• 44 OECD. OECD guidelines for the testing of chemicals, acute oral toxicity-fixed dose procedure (OECD 420). Available at: https://www.oecd-ilibrary.org/docserver/9789264070943-en.pdf?expires=1562950830&id=id&accname=guest&checksum=93E95262DCB300DD7D43C0EB6138D9C4 Accessed December 17, 2001
• 45 OECD. OECD Guidelines for the Testing of Chemicals, Repeated Dose 28-Day Oral Toxicity Study in Rodents (OECD 407). Available at: https://www.oecd-ilibrary.org/docserver/9789264070684-en.pdf?expires=1562951228&id=id&%20accname=guest&checksum=AA8A56414FCD056017B8167F363218FF Accessed October 3, 2008
• 46 OECD. OECD Guidelines for the Testing of Chemicals, Chronic Toxicity Studies (OECD 452). Available at https://www.oecd-ilibrary.org/docserver/9789264071209-en.pdf?expires=1562951326&id=id&accname=guest&checksum=BB25D738DACFA8501574F27124D63D1C 2018. Accessed June 25, 2018